Compare Southwest Airlines Co (LUV) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Recursion Pharmaceuticals Inc — how do they compare? Southwest Airlines Co trades at $41.41 (market cap $20.41B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.31B). The key difference: Southwest Airlines Co is far larger — about 8.8× Recursion Pharmaceuticals Inc's market cap, and Southwest Airlines Co pays a 1.73% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| LUV | RXRX | |
|---|---|---|
Market Cap | $20.41B | $2.31B |
Volume | 4,706,365 | 40,478,768 |
Sector | Industrials | Health |
52-Week High | $54.80 | $6.79 |
52-Week Low | $29.67 | $2.84 |
Typical Hold Time | 65 Days | 22 Days |
Enterprise Value | $23.51B | $1.83B |
Dividend Yield | 1.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.36, down 2.57% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 26.08 and net margin of 2.78%, while recent earnings beat expectations in Q2 2026. Cash flow trends improved significantly in 2026 projections. Analyst consensus is divided with 42% buy ratings and a $49.61 price target representing 20% upside potential.
LUV's transformation initiatives show promise with projected $2 billion EBIT from new fare structures, though high fuel costs and competitive pressures remain risks. The stock offers value with P/S of 0.73 and strong revenue growth outlook, but requires monitoring of Q3 2026 earnings due October 22 for confirmation of the turnaround trajectory.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
